Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Stockholders' Equity (Deficit)

v3.3.1.900
Consolidated Statements of Stockholders' Equity (Deficit) - USD ($)
shares in Thousands, $ in Thousands
Total
Convertible Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Balance at Dec. 31, 2012 $ (25,087) $ 16,676 $ 10 $ 1,048 $ (26,145)
Balance (in shares) at Dec. 31, 2012   15,799 15,066    
Issuance of convertible preferred stock 0 $ 4,294 $ 0 0 0
Issuance of convertible preferred stock (in shares)   4,083 0    
Issuance of stock upon conversion of convertible debt and accrued interest 0 $ 6,490 $ 0 0 0
Issuance of stock upon conversion of convertible debt and accrued interest (in shares)   6,041 0    
Common stock warrants issued in connection with issuance of Series B convertible preferred stock 136 $ (136) $ 0 136 0
Common stock repurchased 0 $ 0 $ 0 0 0
Unamortized debt discounts transferred to equity   0 (2)    
Vesting of early exercised options 4 $ 0 $ 0 4  
Effect of merger and recapitalization of share amounts 0 0 6 (6) 0
Issuance of shares to stockholders of Ekso Bionics Holdings Inc 0 $ 0 $ 5 (5) 0
Issuance of shares to stockholders of Ekso Bionics Holdings Inc (in shares)   0 5,280    
Issuance of common stock upon exercise of stock options 65 $ 0 $ 0 65 0
Issuance of common stock upon exercise of stock options (in shares)   0 771    
Stock-based compensation expense 396 $ 0 $ 0 396 0
Net loss (11,887) 0 0 0 (11,887)
Balance at Dec. 31, 2013 (36,373) $ 27,324 $ 21 1,638 (38,032)
Balance (in shares) at Dec. 31, 2013   25,923 21,115    
Conversion of preferred stock 27,324 $ (27,324) $ 27 27,297 0
Conversion of preferred stock (in shares)   (26,691) 26,691    
Issuance of common stock upon exercise of stock options 2   $ 0 2 0
Issuance of common stock upon exercise of stock options (in shares)     90    
Fair value of warrant liability transferred to equity upon net exercise 282   $ 0 282 0
Fair value of warrant liability transferred to equity upon net exercise (in shares)   767      
Balance at Jan. 14, 2014 (8,765) $ 0 $ 48 29,219 (38,032)
Balance (in shares) at Jan. 14, 2014   0 47,896    
Balance at Dec. 31, 2013 (36,373) $ 27,324 $ 21 1,638 (38,032)
Balance (in shares) at Dec. 31, 2013   25,923 21,115    
Net loss (33,769)        
Balance at Dec. 31, 2014 22,800 $ 0 $ 102 94,499 (71,801)
Balance (in shares) at Dec. 31, 2014   0 101,622    
Balance at Jan. 14, 2014 (8,765) $ 0 $ 48 29,219 (38,032)
Balance (in shares) at Jan. 14, 2014   0 47,896    
Issuance costs (3,339) $ 0 $ 0 (3,339) 0
Issuance of common stock warrants at fair value (10,614) 0 0 (10,614) 0
PPO shares issued for cash 25,300 $ 0 $ 25 25,275 0
PPO shares issued for cash (in shares)   0 25,300    
PPO shares issued upon conversion of 2013 Bridge Notes 5,082 $ 0 $ 5 5,077 0
PPO shares issued upon conversion of 2013 Bridge Notes (in shares)   0 5,000    
Shares issued to consultant in PPO 0   $ 0 0 0
Shares issued to consultant in PPO (in shares)     250    
Fair value of warrant obligation transferred to equity 96 $ 0   96 0
Unamortized debt discounts transferred to equity (947) 0 $ 0 (947) 0
Balance at Jan. 16, 2014 6,813 $ 0 $ 78 44,767 (38,032)
Balance (in shares) at Jan. 16, 2014   0 78,446    
Fair value of warrant anti-dilution feature transferred to equity 27,099 $ 0 $ 0 27,099 0
Issuance of common stock upon exercise of warrants 21,412 $ 0 $ 23 21,389 0
Issuance of common stock upon exercise of warrants (in shares)   0 22,881    
Issuance of common stock upon exercise of stock options 102 $ 0 $ 1 101 0
Issuance of common stock upon exercise of stock options (in shares)   0 295    
Stock-based compensation expense 1,143 $ 0 $ 0 1,143 0
Net loss (33,769) 0 0   (33,769)
Balance at Dec. 31, 2014 22,800 $ 0 $ 102 94,499 (71,801)
Balance (in shares) at Dec. 31, 2014   0 101,622    
Issuance of convertible preferred stock 14,218 $ 0 $ 0 14,218 0
Issuance of convertible preferred stock (in shares)   15 0    
Issuance of warrants in connection with Series A convertible preferred stock recorded as a warrant liability $ (11,700) $ 0 $ 0 (11,700) 0
Conversion of preferred stock (in shares) 2        
Beneficial conversion feature on Series A preferred stock $ 3,300 0 0 3,300 0
Conversion of Series A convertible preferred stock to common stock and accretion of Series A convertible preferred stock discount 1,356 $ 0 $ 1 1,355 0
Conversion of Series A convertible preferred stock to common stock and accretion of Series A convertible preferred stock discount (in shares)   (2) 1,720    
Deemed dividend on Series A convertible preferred stock (4,655) $ 0 $ 0 (4,655) 0
Issuance of common stock for assets acquired from Equipois 1,071 $ 0 $ 1 1,070 0
Issuance of common stock for assets acquired from Equipois (in shares)   0 781    
Issuance of common stock upon exercise of warrants 52 $ 0 $ 0 52 0
Issuance of common stock upon exercise of warrants (in shares)   0 51    
Issuance of common stock upon exercise of stock options 225 $ 0 $ 1 224 0
Issuance of common stock upon exercise of stock options (in shares)   0 1,017    
Stock-based compensation expense 1,731 $ 0 $ 0 1,731 0
Net loss (19,590) 0 0 0 (19,590)
Balance at Dec. 31, 2015 $ 8,808 $ 0 $ 105 $ 100,094 $ (91,391)
Balance (in shares) at Dec. 31, 2015   13 105,191